[{"orgOrder":0,"company":"Aelis Farma","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"AEF0117","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ Indivior","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ Indivior"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Indivior","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AEF0117","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ Aelis Farma","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ Aelis Farma"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Indivior","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"AEF0117","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Aelis Farma \/ Indivior","highestDevelopmentStatusID":"14","companyTruncated":"Aelis Farma \/ Indivior"}]

Find Clinical Drug Pipeline Developments & Deals by Aelis Farma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AEF0117 is an oral drug candidate, being evaluated for its efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD).

                          Brand Name : AEF0117

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 04, 2024

                          Lead Product(s) : AEF0117

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Indivior

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Following the promising results of a Phase 2a study showing that AEF0117 reduced the subjective effects of cannabis and cannabis self-administration in subjects with moderate to severe CUD.

                          Brand Name : AEF0117

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 01, 2022

                          Lead Product(s) : AEF0117

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Recipient : Indivior

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Indivior has entered into a strategic collaboration with Aelis Farma ("Aelis"), a private biotechnology company based in Bordeaux, France, that includes an exclusive option and license agreement (the "Agreement") for the global rights to AEF0117.

                          Brand Name : AEF0117

                          Molecule Type : Small molecule

                          Upfront Cash : $30.0 million

                          June 08, 2021

                          Lead Product(s) : AEF0117

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Indivior

                          Deal Size : $130.0 million

                          Deal Type : Collaboration

                          blank